Classification of Painful or Painless Diabetic Peripheral Neuropathy and Identification of the Most Powerful Predictors Using Machine Learning Models in Large Cross-Sectional Cohorts

Georgios Baskozos (✉ georgios.baskozos@ndcn.ox.ac.uk)  
University of Oxford

Andreas Themistocleous  
University of Oxford

Harry L Hebert  
University of Dundee

Mathilde Pascal  
University of Oxford

Jishi John  
University of Oxford

Brian Callaghan  
University of Michigan Medical School

Helen Laycock  
Imperial College London

Geert Crombez  
Ghent University

Andrew SC Rice  
Imperial College London

Blair H Smith  
University of Dundee

David L.H Bennett  
University of Oxford

Research Article

Keywords: diabetic peripheral neuropathy, machine learning models, harmonised cohorts, area under the precision/recall curve (AUPRC)

Posted Date: November 17th, 2021

DOI: https://doi.org/10.21203/rs.3.rs-1074596/v1
Abstract

Background:

To improve the treatment of painful Diabetic Peripheral Neuropathy (DPN) and associated co-morbidities, a better understanding of the pathophysiology and risk factors for painful DPN is required. Using harmonised cohorts (N = 1230) we have built models that classify painful versus painless DPN.

Methods:

The Random Forest, Adaptive Regression Splines and Naive Bayes machine learning models were trained for classifying painful/painless DPN. Their performance was estimated using cross-validation in large cross-sectional cohorts (N = 935). Models were externally validated in a large population-based cohort (N = 295) in the presence of missing values. Variables were ranked for importance using model specific metrics and marginal effects of predictors were aggregated and assessed at the global level. Model selection was carried out using the Mathews Correlation Coefficient (MCC) and model performance was quantified in the validation set using MCC, the area under the precision/recall curve (AUPRC) and accuracy.

Results:

Random Forest (MCC=0.28, AUPRC = 0.76) and Adaptive Regression Splines (MCC = 0.29, AUPRC = 0.77) were the best performing models and showed the smallest reduction in performance between the training and validation dataset. EQ5D index, the 10-item personality dimensions, HbA1c, Depression and Anxiety t-scores, age and Body Mass Index were consistently amongst the most powerful predictors in classifying painful vs painless DPN.

Conclusions:

Machine learning models trained on large cross-sectional cohorts were able to accurately classify painful or painless DPN on an independent population-based dataset. Painful DPN is associated with more depression, anxiety and certain personality traits. It is also associated with poorer self-reported quality of life, younger age, poor glucose control and high Body Mass Index (BMI). The models showed good performance in realistic conditions in the presence of missing values and noisy datasets. These models can be used either in the clinical context to assist patient stratification based on the risk of painful DPN or return broad risk categories based on user input. Model’s performance and calibration suggest that in both cases they could potentially improve diagnosis and outcomes by changing modifiable factors like BMI and HbA1c control and institute earlier preventive or supportive measures like psychological interventions.

Background

Peripheral neuropathy as a complication of diabetes

The prevalence of Diabetic Peripheral Neuropathy (DPN) is 29-49% in people with diabetes mellitus (1,2). Up to 50% of patients with DPN will develop chronic neuropathic pain (1,3). Painful DPN is characterised by chronic pain that is most severe in the feet (4), but can extend to involve the legs, hands and arms in a typical “glove
and stocking distribution”. The pain is often described as a burning sensation, associated with paraesthesiae or dysaesthesiae and occasionally allodynia (4,5). The last decade has seen significant advances in our ability to characterise the sensory phenotype of DPN using patient-reported sensory symptoms (6) and standardised quantitative sensory testing (7) which facilitate patient stratification (8).

Painful DPN is strongly associated with poor quality of life and psychological co-morbidities such as depression and anxiety disorders (9,10). The mental health burden associated with painful DPN remains an under-recognised and under-treated complication associated with diabetes mellitus. Management of DPN is complicated by several challenges. The condition is under-diagnosed (11), current treatment options are inadequate (3,4), and we do not understand why some patients with DPN develop pain and others do not.

The pathophysiology of painful DPN is most likely a complex interaction of genetic, environmental and psychological factors. For example, a recent review of studies of the risk factors for neuropathic pain reported that clinical and lifestyle factors such as obesity, poor glucose control, hypertension and neuropathy severity were associated with its presence as well as genetic and psychological factors such as depression and anxiety (12). Interactions between risk factors may also be important. For example, we have found that the negative impact of glucose control on neuropathy severity is larger in males than in females, whereas stress and anxiety had larger effects in females (8,13).

In order to improve the treatment of painful DPN and the associated co-morbidities, it is essential that we develop a better understanding of the pathophysiology and risk factors for painful DPN. The DOLORisk project (14) has provided the scientific community with large harmonised datasets that can be exploited in order to better understand the risk factors and build models predicting the development of painful or painless DPN. Moreover, data harmonisation between multiple datasets collected from different centres facilitates estimation of the models performance using cross-validation and rigorous external validation in independent datasets.

**Machine learning**

ML is a technique for statistical learning that involves optimisation in order to minimise the loss of function and optimise the predictive ability. During training an ML algorithm learns patterns and determines the optimal values for its internal parameters from data (15,16). ML is focused on prediction by optimising the discrimination of different classes; no assumptions about the underlying processes that generate data are required and a well performing model does not replace the rigorous statistical techniques needed to infer causality. The advantage of a well-trained ML model is that it can be easily generalised to predict unobserved outcomes on an unknown dataset. In supervised classification, we train an ML algorithm in a training dataset with known classes (e.g. painful vs painless neuropathy), and use the final model to predict classes in new samples. Reducible prediction errors are bias (i.e. the difference between a model’s prediction and the actual value) and variance (i.e. the difference between predictions of different realisations of the model) (17). In this context model training involves a trade-off between bias and variance (18,19). A model with high bias under-fits the data and a model with high variance over-fits the data. A manifestation of over-fitting is a model that has learned nuances of the training data and cannot be generalised in un-observed data. Thus model validation in an independent test dataset is important in order to avoid highly optimistic estimations of real-world model performance.
Another important aspect is how to handle missing data. Every decision taken in training is considered part of the model building and should be benchmarked for its effect on model performance. The same is true for the imputation of missing values in model training, testing and validation. As large clinical cohorts often suffer from missing values in several data points we have developed a framework of utilising multiple imputation of missing values that does not leak information between model training and validation, models the uncertainty introduced due to the imputation, and performs outcome agnostic imputation of the validation datasets simulating model deployment and prediction in the presence of missing values (20,21). Estimates from multiple imputed datasets are aggregated using Rubin's rules (20). Multiple models are then trained in the multiple completed datasets and predictions are aggregated over all the completed instances of the outcome-agnostic imputed validation set. This is a predict-and-aggregate strategy (22,23). We have also taken care to encapsulate all model building decisions in a cross-validation approach that ensures no information leakage between in-fold and out-of-fold instances during cross-validation.

Algorithmic modelling and ML techniques are notorious for their “black box” approach that can obscure meaningful relations between predictors and present spurious associations due to chance or systematic errors as related to the outcome. A lot of work has focused on making ML interpretable (24–26). In the context of a model one can see how changes in predictors influence the model's predictions (26,27) and predictors can be ranked based on model specific or model independent metrics. These techniques allow us to explain and better understand the behaviour of ML algorithms. In the rest of the manuscript we will use the words predictors or features interchangeably.

Predicting diabetes complications

ML has been successfully utilised for predicting (28–30) and developing (31–33) risk equations for diabetes and its complications. Hyperglycaemia, hypertension, obesity, smoking, duration of diabetes and female gender have been identified as risk factors increasing the odds ratio for DPN (30,31,34,35). However, psychological factors have generally not been considered and importantly, only the presence of DPN was usually amongst the endpoints with no distinction between painful and painless neuropathy. ML has been used to predict co-morbid depression in people with diabetes mellitus, finding that female gender, having a higher number of diabetic complications and the presence of chronic pain were amongst the factors most highly correlated with major depression (32). In this study we have used an array of demographics, clinical, quality of life and psychological features to classify painful or painless DPN in the largest (to the best of our knowledge) deeply phenotyped clinical cohort of people with painful or painless DPN (N= 1230) to date. ML was applied in a realistic context that included the presence of missing values and different ways of defining the outcome, i.e. clinical diagnosis or questionnaire based.

Methods

In this study we trained a diverse set of Machine Learning (ML) models to classify painful versus painless DPN in three datasets: a deeply phenotyped clinical cohort developed in the University of Oxford (5); Technion - Israel Institute of Technology; and Imperial College London. We then externally validated these models in a
questionnaire-based phenotyped population cohort developed in the University of Dundee (15). We followed the TRIPOD reporting guidelines (36), supplementary Figure 1.

Datasets

All data used in this study has been generated using the DOLORisk study protocol which has been described elsewhere (14). The total sample size used for training and validating these models was 1230 people with diabetes mellitus, predominantly Type II.

Three large, deeply phenotyped, cross-sectional cohorts (DOLORisk Imperial College London, PINS - University of Oxford (5) and DOLORisk Technion - Israel Institute of Technology, N = 935) were used to train and estimate model's performance using 5-times repeated 10-fold cross-validation. Training datasets had deep clinical phenotyping. Participants were first screened for clinical neuropathy based on symptomatology and DPN was confirmed by abnormalities of nerve conduction studies or Intra Epidermal Nerve Fibre Density (IENFD) (37). Neuropathic Pain (NeuP “pain caused by a lesion or disease of the somatosensory system”) was determined at the time of the clinical assessment according to the NeuP Special Interest Group (NeuPSIG) of the International Association for the Study of Pain (IASP) grading system (38).

The NeuPSIG grading for neuropathic pain was used to grade neuropathic pain.

This is pain with:

1. a distinct neuroanatomically plausible distribution, i.e. pain in symmetrically distributed in the extremities;
2. a history suggestive of a relevant lesion or disease affecting the peripheral or central somatosensory system—diagnosis of diabetes mellitus and a history of neuropathic symptoms including decreased sensation, positive sensory symptoms, e.g., burning, aching pain mainly in the toes, feet, or legs;
3. Demonstration of the distinct neuroanatomically plausible distribution by at least one confirmatory test—presence of clinical signs of peripheral neuropathy, i.e., decreased distal sensation or decreased/absent ankle reflexes;
4. Demonstration of the relevant lesion or disease by at least one confirmatory test—abnormality on either the nerve conduction tests or IENFD.

Possible neuropathic pain fulfills criteria 1 and 2. Probable neuropathic pain fulfills criteria 1, 2 and 3. Definite neuropathic pain fulfills all 4 criteria.

Participants with chronic (> 3 months) probable or definite NeuP were assigned to the NeuP group and participants with possible neuropathic pain were excluded. Participants with no pain or non-NeuP in the extremities were included in the no NeuP group (5,39).

Models were externally validated in the independent GoDARTS-DOLORisk Dundee (40) dataset. This is a clinical cohort, phenotyped for pain and neuropathy using the DOLORisk protocol. GoDARTS participants with type 2 diabetes from Tayside, Scotland were re-phenotyped for neuropathic pain and related traits, by questionnaire, using the DOLORisk core protocol in order to be classified according to the presence and extent of neuropathic pain. A subset of the 1915 GoDARTS- DOLORisk Dundee participants could be classified as
painful/painless DPN using validated questionnaires and screening questions for the presence and anatomical distribution of pain (N = 295), see Outcome Definition for more details. Data from these cohorts were collected between 2012 and mid-2019.

Only variables that were missing in less than 50% of the training and validation datasets were considered as potential predictors. These include clinical, biochemical, demographical and self-reported quality of life data. A complete overview of the training and validation datasets is presented in Table 1. There was no significant difference in the outcome distribution between the training and validation sets. However, the age and Body Mass Index (BMI) of participants were lower in the training dataset and some self-reported quality of life and psychological variables were significantly different between the training and validation datasets. This is reflective of the fact that the training and validation cohorts are independent and comprised of different populations. PROMIS sleep disturbance t-score, Diabetes duration, Cholesterol, low-density lipoprotein (LDL), high-density lipoprotein (HDL), Creatinine and Triglycerides were removed due to high missing ratio (Supplementary tables 1 and 2). The Chronic Kidney Disease (CKD) indicator variable was removed due to very low incidence, i.e. only 9 positives, and 5 instances were removed due to very low HbA1c < 5 not consistent with diabetes mellitus.

Independent variables include the 5-level EQ-5D-5L instrument (41) that comprises assessment of mobility, self-care, usual activities, pain/discomfort and anxiety/depression; the Patient-Reported Outcomes Measurement Information System (PROMIS) depression and anxiety measurement instruments (42); a question assessing the experience of traumatic events before the age of 18 (Trauma); a question investigating whether someone had stayed in hospital for a long period because of a life threatening disease or situation before the age of 18; the extraversion, agreeableness, conscientiousness, emotional stability and openness personality dimension constructs from the ten-item personality inventory (TIPI) (43); a self-reported ever smoked status; self-reported alcohol consumption in an ordered Likert scale; age; gender; BMI and sugar glucose levels (glycated haemoglobin HbA1c). Variables were filtered for zero or near zero variance numerical features, highly correlated features (>0.8 Pearson's correlation coefficient) and factors with very low complexity.

**Outcome definition**

The outcome of this study was painful or painless Diabetic Peripheral Neuropathy (DPN). For the training datasets one or more physicians have defined phenotypes after detailed clinical examination and grading of neuropathic pain as discussed above and in line with IASP and NeuPSIG definitions (37,44). An overview of the training datasets including all independent variables is in Table 2.

For the validation datasets we have used an array of structured, validated questionnaires and screening questions to define phenotypes. The Michigan Neuropathy Screening Instrument (MNSI) (45) questionnaire section alone, with a cut-off value of 3, was used to define diabetic neuropathy. Various cut-offs had been suggested for the MNSI clinical examination and questionnaire instrument (45–47). In these it has been consistently reported that the cut-off of 7 for the questionnaire part when used in combination with clinical examination is too insensitive for stand-alone questionnaire use, whereas a cut-off score of 3 and above for the questionnaire only has been shown to have very good performance (AUC = 0.75, optimal cut-off > 2.0318) (45).
A screening question “Are you currently troubled by pain or discomfort, either all the time or on and off?” was used to define the presence of pain. Chronicity was screened using the question “How long have you been suffering with this pain or discomfort?”, with a cut-off of > 3 months to define the temporal aspect of chronic pain. These questions have been validated and are identical to those used in previous population-based epidemiology studies of pain, including UK Biobank (48,49). Location of pain was assessed using the question “In the past three months; a) which of these pains have you had, b) which one of these pains bothered you the most?” followed by a comprehensive choice of body locations including “Pain in your feet”. The participant was then asked to complete the self-complete version of the “Douleur Neuropathique en 4 Questions” (DN4) questionnaire (50) for the most bothersome pain where a score of 3 and above indicated the presence of NeuP. A definition of possible DPN required the presence of neuropathy as screened by the MNSI and chronic pain in the feet, regardless of whether it was the most bothersome pain present.

The DN4 questionnaire-only version was only considered to remove instances of conflicting evidence, i.e. painful neuropathy with a DN4 score under the cut-off value or painless neuropathy with a DN4 value over the cut-off, using a cut-off value of 3 to indicate the presence of NeuP. This cut-off has been validated to provide the optimal area under the ROC for the questionnaire-only section, i.e. excluding the clinical examination (50).

The presence of diabetes, neuropathy and chronic pain in the feet was used to define painful DPN. The presence of diabetes, neuropathy and no neuropathic pain in the feet defined the group of painless DPN, figure 1.

An overview of the validation dataset is in Table 3. 798 people had painful diabetic neuropathy (617 (66%) in training and 181 (61.4%) in validation sets) and 432 had painless diabetic neuropathy (318 (34%) in training and 114 (38.6) in validation sets). A sensitivity analysis assessing the change of the pooled coefficient estimates of a logistic regression model fitted on the imputed validation dataset showed no or very small sensitivity to various outcome definitions (Supplementary Figure 2). We further assessed the internal consistency of the validation cohort by calculating the Cohen’s Kappa inter-rater agreement between the MNSI question “Do you ever have any burning pain in your legs and/or feet?” and the response to the pain localisation question asking for “Pain in your feet”, We observed a significant (p.value < 0.01), fair agreement between these responses, Kappa = 0.295.

**Missing values and feature construction**

Datasets were largely harmonised and follow the DOLORisk core protocol (39). However, in the Oxford cohort, the Depression, Anxiety and Positive Outlook scale (DAPOS) (51) Anxiety and Depression scores initially used have been replaced with the PROMIS (42) anxiety and depression short forms. Under the assumption that these constructs measured the same quantity in different scales we linked DAPOS to PROMIS scores by scaling them together and then using the derived means and standard deviations to bring them in the same scale as PROMIS t-scores. Questions related to smoking were transformed to an “ever smoking” feature by taking into account the response to questions related to smoking at the time when the questionnaire was completed, clinical examination took place or in the past. The EQ-5D-5L (41) questionnaire was used alongside the UK normative data to obtain the EQ-5D index that was used as an independent variable. Alcohol consumption was transformed to a Likert type scale (0-5) using the following ordered levels: "Never", "Less than 1 day per
month", "1 to 3 days per month", "1 or 2 days per week", "3 or 4 days per week", "Daily or almost daily". HbA1c was transformed to percentages (%) from mmol/mol when it was reported that way.

After removing all variables with >50% of missingness, anxiety and depression t-scores demonstrated the highest rate of missingness (about 45%). We then performed multiple imputations by chained equations using the predictive mean matching algorithm (52). The number of imputations was set equal to the maximum missingness ratio experienced by any variable. Multiple imputation was done separately in the training and validation datasets to prevent information leakage between datasets. In order to accurately and not over-optimistically model the uncertainty introduced due to missing values we performed outcome agnostic imputation of the validation dataset. For this purpose a dataset was created by stacking both the training and imputation datasets and removing the outcome. The density plot of the observed and imputed values are in Supplementary Figures 3 and 4 for the training and validation datasets respectively.

**Statistical Analysis**

In an exploratory analysis before model fitting, dependencies between all independent variables and the outcome were assessed using the chi-square test for categorical data and the Kruskal Wallis test for numerical data comparison between two groups. Model's performance was assessed by calculating overall accuracy as the proportion of the total number of correctly classified instances and the binomial test (p.value < 0.05) was used to assess whether accuracy was higher than the prevalence of the majority class, i.e no-information rate (NIR), the balanced accuracy as the mean of sensitivity and specificity and the Area Under the Precision/Recall Curve (AUPRC). However, all these metrics are sensitive to class imbalance and can lead to the selection of models that severely mis-classify the minority class. Therefore, we used the Matthews Correlation Coefficient (MCC) (53), which is similar to Pearson's correlation coefficient, ranging from -1 to 1 and measures how correlated the prediction is to the true outcome. Moreover, MCC does not change with the substitution of the reference class as it is symmetrical and provides a more robust performance metric than accuracy, balanced accuracy and F1 score (53–55). Models’ calibration was assessed on the validation set by visualising the observed event percentage against the 10 prediction probability deciles. A linear model fitted to the calibration curves, i.e. event rate vs midpoint of the decile bin, was used to estimate the calibration slope and intercept.

Models were not updated nor calibrated after training in order to realistically assess the performance in predicting new data.

**Model training and validation**

We developed a workflow that uses the predict-then-aggregate strategy, after multiple imputation during both model training and validation. This way we modelled the uncertainty due to the imputation in both datasets, did not allow for information leakage between training and validation datasets and encapsulated all model building decisions in resampling and external validation (23). Predictions were aggregated using majority voting, and point estimators were aggregated using the mean and Rubin’s rules to calculate the pooled - total standard deviation from the within/between imputations variance (56). The workflow is visualised in Figure 2. Models were trained on the training dataset using a maximum grid search of 60 tuning parameters optimised
for the higher MCC. Numeric variables were centred and scaled for each cross-validation fold to ensure no information leakage between in and out-of-fold samples. The number of multiple imputations was equal to the highest rate of missingness observed across all variables. During training, we imputed missing values using all independent variables and the outcome. Thus we trained an ensemble of $m=45$ models, optimised for the highest MCC during the 5-times repeated, 10-fold cross-validation. The final model out-of-fold prediction probabilities, MCC, accuracy, balanced accuracy and AUPRC were calculated using Rubin's rules. Partial dependence was also aggregated by calculating the mean marginal probability across imputations.

In validation, we first removed the outcome and pooled together the training and validation data. Then we performed $m=45$ imputations as we did during training. The real outcome was kept unknown during the imputation of the validation set, simulating a real-world scenario of prediction of new data in the presence of missing values. Then we used the ensemble of trained models to predict the outcome on each of the 45 imputed validation datasets, producing $45^2$ predictions. Finally, these predictions were aggregated by majority voting.

We trained a series of models using a set of diverged and well-known algorithms presenting the most significant subdomains of ML. The Random Forest (57) is an algorithm that produces an ensemble of decision trees using bagging, a technique that selects random subsets of potential predictors in order split each node of each growing tree. The Random Forest is also robust to the presence of multicollinearity of independent variables as a subset of predictors is randomly selected for each node split.

The Adaptive Regression Splines (58) is a multi-variable extension of regression that is able to model complex non-linear problems using an ensemble of simple linear functions that in aggregate optimise predictive ability. The algorithm has a built-in backwards elimination variable selection.

Finally, the Naive Bayes classifier as implemented in the e1071 package (59) is a probabilistic classifier that uses the Bayes’ rule to calculate the posterior probability of each class given a configuration of independent predictor variables.

In the case of Random Forests and Adaptive Regression Splines we trained an unweighted version and a weighted version with class weights inversely proportional to the class prevalences. Weighted models should match the probability distribution of the outcome closer than unweighted by having better calibration but could also run a higher risk if over-fitting training data and be less generalisable.

Models were trained in R (60) using the CARET package (61) and mltools (62). Multiple imputation was done using MICE (52). Marginal feature effects were calculated using the IML package (63), plots were rendered using ggplot2 (64) and tables using finalfit (65).

**Interpretability**

In order to understand how independent variables values influenced models outcomes and to provide some interpretability of ML algorithms we calculated the variable importance in a model specific way and then scaled the metrics value to 100 to make them directly comparable. For the Random Forest we used the Gini importance index that calculates the mean decrease in impurity of the nodes produced by a split that uses a
certain variable. For the Multivariate Adaptive Regression Splines we used the built-in backwards variable selection of the model to calculate the reduction in performance estimated by cross-validation when each variable is removed, and for the Naive Bayes model a ROC curve analysis was conducted for each variable.

Moreover, we calculated, aggregated and visualised the marginal effects of all independent variables with a scaled importance of > 10 on each model's outcome prediction. These Partial Dependence Plots (PDP) \((66,67)\) plots represent how the model's outcome was influenced by changes in an independent variable values. Partial Dependence (PD) was calculated by marginalizing the classifier's predicted probability over the distribution of the feature of interest.

PDP not only show the marginal probability of the outcome given certain feature values but also provide an assessment on how robust and accurate is the information that a ML model can learn across the distribution of a feature's values. A one-dimensional plot below each PDP shows the density of the feature values across each whole range. A dense distribution indicates that the PD can be accurately calculated for this range of values, while a sparse distribution shows that we cannot reliably calculate PD and also that there was probably not enough data in our training datasets for a model to learn a meaningful relationship for this feature range. We should also note that, while most ML models use different mechanisms to robustly handle some collinearity of features, PDP is sensitive to multicollinearity.

Partial dependence was aggregated for the whole ensemble of trained models using a customised function that calculated the mean across imputed datasets. In addition, trends of PDPs were estimated and visualised using a LOESS \((68)\) smoothed curve. This analysis highlighted how the different values of each independent variable influenced the models predicted outcome all other things being equal.

**Results**

**Performance estimates**

During cross-validation the performance of the unweighted Random Forest had an MCC of 0.3489 (95% CI = 0.3446 – 0.3531) and the weighted Random Forest an MCC of 0.3396 (CI = 0.3354 – 0.3437). Regarding other scalar metrics, the AUPRC was 0.8116 (CI = 0.8098 – 0.8133) for the unweighted version and 0.8184 (CI = 0.8167 -0.8201) for the weighted version, balanced accuracy was 0.6470 (CI = 0.6451 – 0.6490) for the unweighted and 0.6709 (CI = 0.6688 – 0.6730) for the weighted version.

Adaptive Regression Splines achieved similar performance. It had an MCC of 0.3327 (CI = 0.3286 – 0.3368) for the unweighted and 0.3248 (CI = 0.3207 – 0.3289) for the weighted model. AUPRC was 0.8207 (CI = 0.8191 – 0.8224) for the unweighted and 0.8188 (CI = 0.8171 – 0.8205) for the weighted model. Balanced accuracy was 0.6489 (CI = 0.6470 – 0.6509) and 0.6692 (CI = 0.6670 – 0.6713) for the unweighted and weighted model respectively.

Finally the Naive Bayes classifier had an MCC of 0.3112 (CI = 0.3070 – 0.3154), AUPRC of 0.8123 (CI = 0.8107 – 0.8140) and balanced accuracy of 0.6567 (CI = 0.6546 – 0.6588).
All models had good performance estimates indicating a moderate positive relationship between the outcome and models’ predictions, good balanced accuracy and very good AUPRC, Figure 3.

**Variable profiling**

Model specific variable profiling revealed that a specific subset of variables were consistently amongst the most powerful predictors. These included quality of life, personality and psychology traits, age, and glucose control (Figure 4). The built-in backwards feature elimination of the Adaptive Regression Splines algorithm revealed that the best performance was achieved when it considered the EQ5D index, TIPI extraversion and openness, HbA1c, Depression and Anxiety t-scores and age in descending order. EQ5D index, psychology and personality traits were always amongst the top predictors. Random Forest, based on the mean decrease on node impurity, ranked high the importance of BMI, Age and glucose control. Regarding modifiable lifestyle factors, Random Forest models also used alcohol consumption and smoking as predictive features, albeit with lower importance. Naive Bayes classifier produced a similar ranking with the addition of ranking alcohol consumption and experience of traumatic events before the age of 18 as having high importance. In all models, gender was not identified amongst the most powerful predictors although it was important enough to be included amongst the independent variables used in the final trained models. Weighted models had similar feature rankings to unweighted ones, with the noticeable difference of the inclusion of the alcohol consumption scale in the final model of the weighted Adaptive Regression Splines. We should also note that the Adaptive Regression Splines algorithm achieved its best performance using only 7 out of the 16 potential predictors.

**Feature effects**

The Adaptive Regression Splines classifier was more likely to predict painful DPN with lower EQ5D index (Figure 5, A), indicating worse quality of life and showed a clear elbow around a cut-off threshold of 0.5, lower TIPI extraversion (Figure 5, B) for most of the independent variable’s range, lower openness up to a value of 5 and then with increased prevalence for the top two openness values 6-7 (Figure 5, C), and higher HbA1c (Figure 5, D) indicating worse blood glucose level control.

The EQ5D index (Figure 6, A) had the same influence on the Random Forests predictions. Higher BMI showed increased marginal probability for painful DPN (Figure 6, B) for the part of the range where PD could be accurately calculated. The effect was non-monotonic for the part of the range where we had sparse density of values. Higher values of the PROMIS Depression t-score were associated with increased probability for a participant to be classified as having painful DPN (Figure 6, C). Age (Figure 6, D) had a similar non-monotonic effect as BMI. Ages 40-60 showed an increased marginal probability for painful DPN, while higher ages, where marginal probability was calculated with higher accuracy due to the higher density of values, showed a lower marginal probability for painful DPN. HbA1c (Figure 6, E) showed again that worse blood glucose control increased the probability of a classification to the painful DPN group. Anxiety (Figure 6, F) showed a similar influence to Depression for the part of the feature’s range that had high density of values. TIPI extraversion and openness (Figure 6, G, H) were similar and had the same effect in Random Forest as in the Adaptive Regression Splines. Higher emotional stability increased the marginal probability of painful DPN (Figure 6, I) and the same was observed for conscientiousness (Figure 6, L). For the part of range where PD could be accurately
estimated, higher TIPI agreeableness was negatively associated with painful DPN (Figure 6, J). Higher alcohol consumption was consistently associated with decreased marginal probability of painful DPN (Figure 6, K).

The influence of EQ5D values in the Naive Bayes classifier (Figure 7, A) was very similar with that which was observed in the Adaptive Regression Splines and the Random Forest. Depression and Anxiety had a strong effect on prediction (Figure 7 B, C) and were both positively associated with increased marginal probability for painful DPN. Again alcohol consumption and Age were negatively associated with a prediction of painful DPN (Figure 7, D, E). Higher HbA1c increased the marginal probability for painful DPN (Figure 7, F). Finally, traumatic experiences under the age of 18 increased the marginal probability for painful DPN (Figure 7, H). The same relationship between higher BMI values and higher probability for painful DPN was observed for the part of the BMI's range where the model could learn meaningful relationships (Figure 7, I). We should note that for most features, with the exception of EQ5D, Alcohol consumption and to an extent HbA1c, models showed unstable behaviour manifested with erratic changes in the marginal probabilities of the sparse values of the features’ range.

Validation

Model validation took place in the independent cohort of 295 people. All ensembles of 45 strong trained classifiers predicted and aggregated prediction on all 45 imputed validation sets. Models' performance was benchmarked using the MCC, AUPRC, balanced accuracy, accuracy and the p.value of the associated binomial test (Figure 8, A). The AUPRC was very good for all models. However only the unweighted versions of Random Forest and Adaptive Regression Splines had an overall accuracy significantly better than the NIR (p value < 0.05) and were also the models that showed the highest MCC.

In general, performance was markedly reduced between training and validation (Figure 8 B-D). Regarding the most important and robust metric MCC, Random Forest (0.28) and Adaptive Regression Splines (0.29) showed the smallest reduction in performance whilst still achieving good moderate positive correlation between predicted and observed outcomes. Additionally, considering MCC unweighted models markedly outperformed weighted ones (Figure 8B-D).

Model calibration is presented in Figure 9 A. Adaptive Regression Splines, Random forest, but not Naive Bayes, showed a monotonic increasing event rate for increased positive (painful DPN) class probabilities. The intercept and slope of the linear model fitted to calibration curves, i.e. event rate vs midpoint of decile bin, indicated good calibration for Random Forest and Adaptive Regression Splines, (Figure 9, B). Intercept estimates showed that the former slightly over-fitted the data whereas the latter slightly under-fitted. However, the slope of both models was very good given that they had not been calibrated on the validation set. All models gained power moderately fast, requiring approximately 50% of the samples to correctly identify 60% of painful DPN events.

Discussion

This study is one of the largest and most comprehensively phenotyped cohort of people with DPN, in which ML is applied to classify painful versus painless neuropathy. ML has been used in other studies focusing on
diabetic neuropathic pain or neuropathy versus no pain or no neuropathy with smaller sample sizes ranging from 327 to 943 instances (29, 69, 70). Given the large effects of the presence of neuropathy we consider the distinction of painful vs painless DPN to be more challenging for a differential diagnosis, classification or prediction. Given this, we have managed to train models that had good to very good performance on an independent validation dataset.

Importantly the training and validation cohorts were collected at different sites, representing different populations and compiled using different methods. Nevertheless they all follow the core DOLORisk protocol, highlighting the importance of large harmonised cohorts.

This study used statistical learning techniques for painful/painless DPN in a realistic framework that accounts for the presence of missing values both during model training and when predicting new instances. In addition, we have taken measures to avoid over-estimating a model’s performance. The comparison of scalar metrics often used in statistical learning, including ML, highlights that the usage of accuracy or the AUC alone can significantly overestimate the model’s performance. Importantly the two best models in the current study, i.e. Random Forests and Adaptive Regression Splines, showed the smallest reduction in performance in MCC between the training estimate and the validated performance, better calibration and an overall accuracy significantly better than the prevalence of the majority class. The fact that the models’ performances were reduced in validation highlights the importance of using an independent validation dataset. The optimistic performance estimates during model training are also known as over-fit, indicating a model with high variance that has learned nuances of the training dataset that are not necessarily generalisable to the new unknown instances. In addition, datasets that are imbalanced, as is often the case for clinical cohorts, where a condition of interest can be at the same time serious and rare, can also bias some performance metrics and produce highly optimistic estimates. This is a well-known issue in model benchmarking and validation (24, 66, 67) but is sometimes ignored in ML studies. Simpler and more parsimonious models are usually found to be more robust, trading off some variance with bias, and this could be the case with Adaptive Regression Splines, the algorithm that created the most parsimonious model in this study, and that also achieved the best performance in the validation dataset.

In the current study we have opted for using model-agnostic techniques to provide feature rankings and interpretability in order to highlight how independent variables’ values influenced the prediction probabilities of the trained models. Self-reported quality of life, psychological and personality traits have consistently been the most powerful predictors of painful DPN both in the current study and in previous studies using different modelling techniques (70, 72, 73). BMI was a modifiable factor that was positively associated with painful DPN. Interestingly alcohol consumption is shown to be negatively associated with painful DPN. Although alcohol consumption has been found to be negatively associated with chronic pain (74), genetic randomisation had not found evidence supporting this protective effect and shown that most probably the direction of causality is that chronic pain reduces alcohol consumption (75). Finally, age was found to have a complex non-monotonic relationship with the development of painful DPN. Although people with painful DPN are younger on average than those with painless DPN, this is mostly driven by a greater prevalence in the 40-60 age group. These kinds of complex relationships highlight the need of advanced statistical learning techniques in order to accurately model the development of painful or painless DPN. In addition, the sensitivity of PD on the density
of the values of the respective feature highlights the need to use the largest possible clinical cohorts to allow ML models to learn meaningful relationships from data.

These models can be used either in the clinical context to assist patient stratification based on the risk of developing painful DPN if proven to be valid in a prospective study, or in the form of an online calculator that can return broad risk categories based on user input. Models’ performance and calibration prove that in both cases they can help timely diagnosis and prognosis, and could ultimately help patients and healthcare personnel to improve outcomes in those at highest risk by changing modifiable factors such as BMI and HbA1c control and institute earlier treatments including medication and/or psychological interventions.

The main limitation of this study is the fact that the cohorts used were cross-sectional, therefore we cannot consider this a prognostic modelling study in the temporal sense. However, the GoDARTS validation dataset is a longitudinal cohort and the PINS and DOLORisk Imperial cohorts are followed up for 2- and 5-year outcome re-phenotyping. We will use this data in the future to update and re-validate the models.

**Conclusions**

Machine learning models trained on large cross-sectional cohorts were able to accurately classify painful or painless DPN on an independent population-based dataset. Painful DPN was strongly associated with poorer self-reported quality of life, younger age, poor glucose control, high BMI and a number of psychological/personality factors. These models showed good performance in realistic conditions in the presence of missing values and noisy datasets.

**Abbreviations**

DPN: Diabetic Peripheral Neuropathy  
ML: Machine Learning  
PROMIS: Patient-Reported Outcomes Measurement Information System  
TIPI: Ten-Item Personality Pnventory  
BMI: Body Mass Index  
HbA1c: Hemoglobin A1c  
CKD: Chronic Kidney Disease  
MNSI: Michigan Neuropathy Screening Instrument  
DN4: Douleur Neuropathique en 4 Questions  
DAPOS: Depression, Anxiety and Positive Outlook scale  
NIR: No-information Rate
AUPRC : Area Under the Precision/Recall Curve

MCC: Mathews’ Correlation Coefficient

PD: Partial Dependence

Declarations

Ethics approval and consent to participate

All data used and analysed in this study has been previously collected. Ethics consent for all studies has been previously approved by their regional ethics committees as required by national law. The “Pain In Neuropathy Study (PiNS)”, University of Oxford UK, has been approved by the National Research Ethics Service - West London REC 3 (No.: 10/H07056/35). “DOLORisk Dundee: Development of a Risk Model for (severe) Neuropathic Pain”, University of Dundee UK, has been approved by the Health Research Authority - NRES Committee Yorkshire & The Humber - South Yorkshire (REC: 15/YH/0285, IRAS project ID: 181986). “DOLORisk: Understanding risk factors and determinants for neuropathic pain”, Imperial College London has been approved by London - Bromley Research Ethics Committee (REC: 16/LO/1470, IRAS project ID: 209707). “Understanding Risk Factors and Determinants for Neuropathic Pain”, Technion - Israel Institute of Technology, has been approved by the Helsinki Committee of Rambam Health Care Campus (Reference: 0052-15-RNB, NCT: NCT02402361)

Consent for publication

NA

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author on reasonable request and under permission from the DOLORisk consortium. All scripts for data pre-process, model training, validation and Figure generation are available in http://github.com/gbaskozos/ML_DPN_Painful_Painless.

Competing interests

Andrew SC Rice reports conflicts of interest occurring in last 24 months:

• ASCR undertakes consultancy and advisory board work for Imperial College Consultants- ASCR undertakes consultancy and advisory board work for Imperial College Consultants- in the last 36 months this has included remunerated work for: Abide, Confo, Vertex, Pharmanovo, Lateral, Novartis, Mundipharma, Orion, Shanghai SIMR BiotechAsahi Kasei, Toray & Theranexis
• ASCR was the owner of share options in Spinifex Pharmaceuticals from which personal benefit accrued upon the acquisition of Spinifex by Novartis in July 2015. The final payment was made in 2019.

• ASCR is named as an inventor on patents:
  • Rice A.S.C., Vandevoorde S. and Lambert D.M Methods using N-(2-propenyl)hexadecanamide and related amides to relieve pain. WO 2005/079771
  • Okuse K. et al Methods of treating pain by inhibition of vgf activity EP13702262.0/ WO2013 110945

• Councillor International Association Study of Pain

• National Institute for Health Research (NIHR) - Chair of the Trial Steering Committee (TSC) for the OPTION-DM trial.

• Advisor British National Formulary

• Member Joint Committee on Vaccine and Immunisation- varicella sub-committee

• Analgesic Clinical Trial Translation: Innovations, Opportunities, and Networks (ACTTION) steering committee member

• Non Freezing Cold Injury Independent Senior Advisory Committee (NISAC): Member

• Medicines and Healthcare products Regulatory Agency (MHRA), Commission on Human Medicines - Neurology, Pain & Psychiatry Expert Advisory Group

**Funding**

This work was supported by Diabetes UK under grant agreement 19/0005984 and the European Union's Horizon 2020 research and innovation programme under grant agreement No 633491 (DOLORisk) and funding from the MRC and Versus Arthritis to the PAINSTORM consortium as part of the Advanced Pain Discovery Platform (MR/W002388/1). No funding body had any role in the design of the study and collection, analysis, and interpretation of data and in writing the manuscript.

**Authors' contributions**

Conceptualisation, Writing - Original Draft: G.B and D.L.B. Supervision: D.L.B, B.H.S. A.R. G.C. Methodology, Visualisation, Software, Formal analysis: G.B. Investigation, Data Curation, Resources: A.T, H.L.H, M.P, J.J, B.C. Project administration: M.P. Funding acquisition: D.L.B, G.B, B.H.S., A.S.C.R, G.C. All authors read and approved the final manuscript.

**Acknowledgements**
The authors would like to acknowledge the use of the University of Oxford Advanced Research Computing (ARC) facility in carrying out this work (76).

References

1. Abbott CA, Malik RA, van Ross ERE, Kulkarni J, Boulton AJM. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care. 2011 Oct;34(10):2220–4.
2. Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population. Diabetologia. 1993 Feb;36(2):150–4.
3. Bouhassira D, Letanoux M, Hartemann A. Chronic pain with neuropathic characteristics in diabetic patients: a French cross-sectional study. PLoS ONE. 2013;8(9):e74195.
4. Tesfaye S, Vileikyte L, Rayman G, Sindrup SH, Perkins BA, Baconja M, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011 Oct;27(7):629–38.
5. Themistocleous AC, Ramirez JD, Shillo PR, Lees JG, Selvarajah D, Orengo C, et al. The Pain in Neuropathy Study (PiNS): a cross-sectional observational study determining the somatosensory phenotype of painful and painless diabetic neuropathy. PAIN. 2016 May;157(5):1132–45.
6. Bouhassira D, Attal N, Fermanian J, Alchaar H, Gautron M, Masquelier E, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004 Apr;108(3):248–57.
7. Rolke R, Baron R, Maier C, Tölle TR, Treede R-D, Beyer A, et al. Quantitative sensory testing in the German Research Network on Neuropathic Pain (DFNS): standardized protocol and reference values. Pain. 2006 Aug;123(3):231–43.
8. Themistocleous AC, Crombez G, Baskozos G, Bennett DL. Using stratified medicine to understand, diagnose, and treat neuropathic pain. PAIN. 2018 Sep;159:S31.
9. Dermanovic Dobrota V, Hrabac P, Skegro D, Smiljanic R, Dobrota S, Prkacin I, et al. The impact of neuropathic pain and other comorbidities on the quality of life in patients with diabetes. Health Qual Life Outcomes. 2014 Dec 3;12:171.
10. Jain R, Jain S, Raison CL, Maletic V. Painful diabetic neuropathy is more than pain alone: examining the role of anxiety and depression as mediators and complicators. Curr Diab Rep. 2011 Aug;11(4):275–84.
11. Herman WH, Kennedy L. Underdiagnosis of Peripheral Neuropathy in Type 2 Diabetes. Diabetes Care. 2005 Jun 1;28(6):1480–1.
12. Hébert HL, Veluchamy A, Torrance N, Smith BH. Risk factors for neuropathic pain in diabetes mellitus. Pain. 2017 Apr;158(4):560–8.
13. Sieberg CB, Taras C, Gomaa A, Nickerson C, Wong C, Ward C, et al. Neuropathic pain drives anxiety behavior in mice, results consistent with anxiety levels in diabetic neuropathy patients. PAIN Reports. 2018 Jun;3(3):e651.
14. Pascal MMV, Themistocleous AC, Baron R, Binder A, Bouhassira D, Crombez G, et al. DOLORisk: study protocol for a multi-centre observational study to understand the risk factors and determinants of
neuropathic pain. Wellcome Open Research. 2018 May 29;3:63.

15. Mitchell TM. Machine Learning. New York: PN; 1990. 432 p.

16. Breiman L. Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author). Statist Sci. 2001 Aug;16(3):199–231.

17. Geman S, Bienenstock E, Doursat R. Neural Networks and the Bias/Variance Dilemma. Neural Computation. 1992 Jan;4(1):1–58.

18. Kohavi R, Wolpert D. Bias plus variance decomposition for zero-one loss functions. In: Proceedings of the Thirteenth International Conference on International Conference on Machine Learning. San Francisco, CA, USA: Morgan Kaufmann Publishers Inc.; 1996. p. 275–83. (ICML’96).

19. Holte RC. Very Simple Classification Rules Perform Well on Most Commonly Used Datasets. Machine Learning. 1993 Apr 1;11(1):63–90.

20. Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol. 2009 Jul 28;9:57.

21. Alasalmi T, Koskimäki H, Suutala J, Röning J. Classification Uncertainty of Multiple Imputed Data. In: 2015 IEEE Symposium Series on Computational Intelligence. 2015. p. 151–8.

22. Belanche LA, Kobayashi V, Aluja T. Handling missing values in kernel methods with application to microbiology data. Neurocomputing. 2014 Oct 2;141:110–6.

23. Alasalmi T, Koskimäki H, Suutala J, Röning J. Classification Uncertainty of Multiple Imputed Data. In: 2015 IEEE Symposium Series on Computational Intelligence. 2015. p. 151–8.

24. Ribeiro MT, Singh S, Guestrin C. “Why Should I Trust You?”: Explaining the Predictions of Any Classifier. arXiv:160204938 [cs, stat] [Internet]. 2016 Feb 16 [cited 2018 Nov 7]; Available from: http://arxiv.org/abs/1602.04938

25. Goldstein A, Kapelner A, Bleich J, Pitkin E. Peeking Inside the Black Box: Visualizing Statistical Learning with Plots of Individual Conditional Expectation. arXiv:13096392 [stat] [Internet]. 2013 Sep 24 [cited 2018 Nov 7]; Available from: http://arxiv.org/abs/1309.6392

26. Apley DW. Visualizing the Effects of Predictor Variables in Black Box Supervised Learning Models. arXiv:161208468 [stat] [Internet]. 2016 Dec 26 [cited 2019 Mar 26]; Available from: http://arxiv.org/abs/1612.08468

27. Greenwell BM, Boehmke BC, McCarthy AJ. A Simple and Effective Model-Based Variable Importance Measure. arXiv e-prints. 2018 May 1;1805:arXiv:1805.04755.

28. Diabetic peripheral neuropathy class prediction by multicategory support vector machine model: a cross-sectional study [Internet]. [cited 2018 Feb 20]. Available from: https://www.e-epih.org/journal/view.php?doi=10.4178/epih.e2016011

29. Kavakiotis I, Tsavel O, Saligogou A, Maglaveras N, Vlahavas I, Chouvarda I. Machine Learning and Data Mining Methods in Diabetes Research. Comput Struct Biotechnol J. 2017;15:104–16.

30. Machine Learning Methods to Predict Diabetes Complications - Arianna Dagliati, Simone Marini, Lucia Sacchi, Giulia Cogni, Marsida Teliti, Valentina Tibollo, Pasquale De Cata, Luca Chiovato, Riccardo Bellazzi,
31. Lagani V, Chiarugi F, Thomson S, Fursse J, Lakasing E, Jones RW, et al. Development and validation of risk assessment models for diabetes-related complications based on the DCCT/EDIC data. Journal of Diabetes and its Complications. 2015 May 1;29(4):479–87.

32. Jin H. Development of a Clinical Forecasting Model to Predict Comorbid Depression Among Diabetes Patients and an Application in Depression Screening Policy Making. Prev Chronic Dis [Internet]. 2015 [cited 2018 Oct 16];12. Available from: https://www.cdc.gov/pcd/issues/2015/15_0047.htm

33. DuBrava S, Mardekan J, Sadosky A, Bienen EJ, Parsons B, Hopps M, et al. Using Random Forest Models to Identify Correlates of a Diabetic Peripheral Neuropathy Diagnosis from Electronic Health Record Data. Pain Med. 2017 Jan 1;18(1):107–15.

34. Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials. The Lancet Diabetes & Endocrinology. 2017 Oct 1;5(10):788–98.

35. Cade WT. Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting. Phys Ther. 2008 Nov 1;88(11):1322–35.

36. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): The TRIPOD statement | The EQUATOR Network [Internet]. [cited 2019 Jul 21]. Available from: https://www.equator-network.org/reporting-guidelines/tripod-statement/

37. Tesfaye S, Boulton AJM, Dyck PJ, Freeman R, Horowitz M, Kempler P, et al. Diabetic Neuropathies: Update on Definitions, Diagnostic Criteria, Estimation of Severity, and Treatments. Diabetes Care. 2010 Oct;33(10):2285–93.

38. Treede R-D, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology. 2008 Apr 29;70(18):1630–5.

39. Pascal MMV, Themistocleous AC, Baron R, Binder A, Bouhassira D, Crombez G, et al. DOLORisk: study protocol for a multi-centre observational study to understand the risk factors and determinants of neuropathic pain. Wellcome Open Research. 2019 Feb 1;3:63.

40. Hébert HL, Shepherd B, Milburn K, Veluchamy A, Meng W, Carr F, et al. Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). Int J Epidemiol. 2018 Apr 1;47(2):380–381j.

41. EuroQol Group. EuroQol—a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199–208.

42. Hays RD, Spritzer KL, Schalet BD, Cella D. PROMIS®-29 v2.0 profile physical and mental health summary scores. Qual Life Res. 2018 Jul;27(7):1885–91.

43. Gosling SD, Rentfrow PJ, Swann Jr. WB. A very brief measure of the Big-Five personality domains. Journal of Research in Personality. 2003;37(6):504–28.

44. Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DLH, Bouhassira D, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016;157(8):1599–606.

45. Herman WH, Pop-Busui R, Braffett BH, Martin CL, Cleary PA, Albers JW, et al. Use of the Michigan Neuropathy Screening Instrument as a measure of distal symmetrical peripheral neuropathy in Type 1
diabetes: results from the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications. Diabet Med. 2012 Jul;29(7):937–44.

46. Lunetta M, Le Moli R, Grasso G, Sangiorgio L. A simplified diagnostic test for ambulatory screening of peripheral diabetic neuropathy. Diabetes Research and Clinical Practice. 1998 Mar 1;39(3):165–72.

47. Moghtaderi A, Bakhshipour A, Rashidi H. Validation of Michigan neuropathy screening instrument for diabetic peripheral neuropathy. Clinical Neurology and Neurosurgery. 2006 Jul 1;108(5):477–81.

48. Sudlow C, Gallacher J, Allen N, Beral V, Burton P, Danesh J, et al. UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age. PLOS Medicine. 2015 Mar 31;12(3):e1001779.

49. Elliott AM, Smith BH, Penny Kl, Smith WC, Chambers WA. The epidemiology of chronic pain in the community. Lancet. 1999 Oct 9;354(9186):1248–52.

50. Spallone V, Morganti R, D'Amato C, Greco C, Cacciotti L, Marfia GA. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med. 2012 May;29(5):578–85.

51. Pincus T, Rusu A, Santos R. Responsiveness and construct validity of the depression, anxiety, and positive outlook scale (DAPOS). Clin J Pain. 2008 Jun;24(5):431–7.

52. Buuren S van, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations in R. Journal of Statistical Software. 2011;45(3):1–67.

53. Chicco D, Jurman G. The advantages of the Matthews correlation coefficient (MCC) over F1 score and accuracy in binary classification evaluation. BMC Genomics. 2020 Jan 2;21(1):6.

54. Mathew J, Pang CK, Luo M, Leong WH. Classification of Imbalanced Data by Oversampling in Kernel Space of Support Vector Machines. IEEE Transactions on Neural Networks and Learning Systems. 2018 Sep;29(9):4065–76.

55. Boughorbel S, Jarray F, El-Anbari M. Optimal classifier for imbalanced data using Matthews Correlation Coefficient metric. PLOS ONE. 2017 Jun 2;12(6):e0177678.

56. Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Medical Research Methodology. 2009 Jul 28;9(1):57.

57. Breiman L. Random Forests. Machine Learning. 2001 Oct 1;45(1):5–32.

58. Friedman JH. Multivariate Adaptive Regression Splines. The Annals of Statistics. 1991 Mar;19(1):1–67.

59. Meyer D, Dimitriadou E, Hornik K, Weingessel A, Leisch F. e1071: Misc Functions of the Department of Statistics, Probability Theory Group (Formerly: E1071), TU Wien [Internet]. 2021. Available from: https://CRAN.R-project.org/package=e1071

60. R Core Team. R: A Language and Environment for Statistical Computing [Internet]. Vienna, Austria: R Foundation for Statistical Computing; 2021. Available from: https://www.R-project.org/

61. Kuhn M. caret: Classification and Regression Training [Internet]. 2021. Available from: https://CRAN.R-project.org/package=caret

62. Gorman B. mltools: Machine Learning Tools [Internet]. 2018. Available from: https://CRAN.R-project.org/package=mltools
Tables

Table 1

Descriptive summary statistics for all datasets. Set index indicates the training or validation dataset. Numerical variables are represented by the median and Inter Quantile Range (IQR) in brackets, categorical variables by the absolute occurrence and percentage in brackets. Columns hold from left to right data for the Training, Validation and both datasets together. Right most column holds the p.value of the comparison between...
Training and Validation datasets using the chi-square test for categorical variables or the Kruskal-Wallis test for numerical variables.
| Dependent: Set Index       |         | Train      | Validation | Total     | p.value |
|---------------------------|---------|------------|------------|-----------|---------|
| Center                    | Dundee  | 0 (0.0)    | 295 (100.0)| 295 (24.0)| <0.001  |
| Imperial                  |         | 180 (19.3) | 0 (0.0)    | 180 (14.6)|         |
| Oxford                    |         | 557 (59.6) | 0 (0.0)    | 557 (45.3)|         |
| Technion                  |         | 198 (21.2) | 0 (0.0)    | 198 (16.1)|         |
| EQ5D_Index                | Median (IQR) | 0.7 (0.6 to 0.8) | 0.7 (0.5 to 0.8) | 0.7 (0.5 to 0.8) | 0.015 |
| Depression_tscore         | Median (IQR) | 49.4 (42.2 to 56.8) | 52.0 (41.0 to 58.7) | 49.4 (41.0 to 57.5) | 0.001 |
| Anxiety_tscore            | Median (IQR) | 45.9 (37.1 to 56.4) | 51.4 (40.3 to 57.5) | 48.5 (40.3 to 56.4) | 0.001 |
| Sleep_Disturbance_tscore  | Median (IQR) | 56.3 (50.1 to 59.4) | 51.8 (49.6 to 54.4) | 53.3 (49.7 to 57.8) | <0.001 |
| Trauma                    | No      | 417 (44.6) | 184 (62.4) | 601 (48.9) | 0.378   |
|                           | Yes     | 194 (20.7) | 99 (33.6)  | 293 (23.8) |         |
|                           | (Missing)| 324 (34.7) | 12 (4.1)   | 336 (27.3) |         |
| Hospital_stay             | No      | 529 (56.6) | 230 (78.0) | 759 (61.7) | 0.649   |
|                           | Yes     | 81 (8.7)   | 31 (10.5)  | 112 (9.1)  |         |
|                           | (Missing)| 325 (34.8) | 34 (11.5)  | 359 (29.2) |         |
| TIPIExtraversion          | Median (IQR) | 4.0 (3.0 to 5.0) | 4.0 (3.0 to 5.0) | 4.0 (3.0 to 5.0) | 0.280 |
| TIPIAgreeableness         | Median (IQR) | 5.0 (4.0 to 6.0) | 5.0 (4.0 to 6.0) | 5.0 (4.0 to 6.0) | 0.531 |
| TIPIConscientiousness     | Median (IQR) | 6.0 (4.5 to 6.5) | 5.5 (4.5 to 6.5) | 6.0 (4.5 to 6.5) | 0.001 |
| TIPIEmotionalStability    | Median (IQR) | 5.0 (4.0 to 6.5) | 4.5 (4.0 to 6.0) | 4.5 (4.0 to 6.5) | 0.145 |
| TIPIOpenness              | Median (IQR) | 5.0 (4.0 to 6.0) | 4.5 (4.0 to 5.6) | 4.5 (4.0 to 6.0) | 0.069 |
| Ever_smoked_status        | No      | 312 (33.4) | 116 (39.3) | 428 (34.8) | 0.001   |
|                           | Yes     | 296 (31.7) | 177 (60.0) | 473 (38.5) |         |
|                           | (Missing)| 327 (35.0) | 2 (0.7)    | 329 (26.7) |         |
| Alcohol_consumption       | Never   | 201 (21.5) | 88 (29.8)  | 289 (23.5) | 0.014   |
|                           | Less than 1 day per month | 119 (12.7) | 75 (25.4)  | 194 (15.8) |         |
|                           | 1 to 3 days per | 74 (7.9)   | 50 (16.9)  | 124 (10.1) |         |
| Month Frequency (n) | 1 or 2 days per week | No | Yes | (Missing) |
|--------------------|----------------------|----|-----|-----------|
| 1 or 2 days per week | 102 (10.9) | 34 (11.5) | 136 (11.1) | 327 (35.0) |
| 3 or 4 days per week | 44 (4.7) | 24 (8.1) | 68 (5.5) | 3 (1.0) |
| Daily or almost daily | 68 (7.3) | 21 (7.1) | 89 (7.2) | 330 (26.8) |

| Alcohol_consumption_likert | Median (IQR) | 1.0 (0.0 to 3.0) | 1.0 (0.0 to 3.0) | 1.0 (0.0 to 3.0) | 0.412 |
| Alcohol_status | No | 201 (21.5) | 88 (29.8) | 289 (23.5) | 0.422 |
| Yes | 407 (43.5) | 204 (69.2) | 611 (49.7) | |
| (Missing) | 327 (35.0) | 3 (1.0) | 330 (26.8) | |

| PCS_score | Median (IQR) | 10.0 (3.0 to 23.0) | 8.0 (4.0 to 20.0) | 10.0 (3.0 to 22.0) | 0.319 |
| MNSI_score | Median (IQR) | 5.0 (3.0 to 7.0) | 4.0 (3.0 to 6.0) | 5.0 (3.0 to 6.0) | 0.146 |
| DN4_score | Median (IQR) | 4.0 (3.0 to 6.0) | 3.0 (2.0 to 5.0) | 4.0 (3.0 to 6.0) | <0.001 |
| Age | Median (IQR) | 68.0 (60.0 to 74.0) | 69.0 (63.0 to 77.0) | 68.0 (61.0 to 74.0) | 0.006 |
| Gender | Female | 300 (32.1) | 104 (35.3) | 404 (32.8) | 0.335 |
| Male | 634 (67.8) | 190 (64.4) | 824 (67.0) | |
| (Missing) | 1 (0.1) | 1 (0.3) | 2 (0.2) | |
| BMI | Median (IQR) | 29.0 (26.0 to 32.9) | 31.2 (27.8 to 35.5) | 29.4 (26.2 to 33.5) | <0.001 |
| HBA1C | Median (IQR) | 7.4 (6.6 to 8.5) | 7.4 (6.7 to 8.7) | 7.4 (6.7 to 8.5) | 0.165 |
| Diabetes_Duration | Median (IQR) | 13.5 (8.0 to 20.0) | 15.0 (12.0 to 20.0) | 15.0 (11.0 to 20.0) | 0.005 |
| Cholesterol | Median (IQR) | 4.1 (3.5 to 4.6) | 3.9 (3.4 to 4.4) | 3.9 (3.4 to 4.5) | 0.141 |
| LDL | Median (IQR) | 2.1 (1.8 to 2.8) | 2.0 (1.5 to 2.5) | 2.0 (1.6 to 2.5) | 0.159 |
| HDL | Median (IQR) | 1.2 (1.0 to 1.4) | 1.1 (0.9 to 1.3) | 1.1 (0.9 to 1.3) | 0.018 |
| Creatinine | Median (IQR) | 75.0 (66.0 to 86.5) | 80.0 (64.0 to 99.0) | 79.5 (65.0 to 96.0) | 0.124 |
| TRIGLYCERIDES | Median (IQR) | 1.7 (1.2 to 2.0) | 1.8 (1.3 to 2.6) | 1.7 (1.3 to 2.5) | 0.041 |
| CKD | No | 926 (99.0) | 272 (92.2) | 1198 | <0.001 |
Table 2

Descriptive summary statistics for the training dataset. Outcome variable indicates painful or painless DPN. Numerical variables are represented by the median and Inter Quantile Range (IQR) in brackets, categorical variables by the absolute occurrence and percentage in brackets. Columns hold from left to right data for people with Painful DPN, Painless DPN and the total of the Training datasets. Right most column holds the p.value of the comparison between Painful and Painless DPN using the chi-square test for categorical variables or the Kruskal Wallis test for numerical variables.
| Dependent: Outcome       | Painful_neuropathy | Painless_neuropathy | Total | p.value |
|-------------------------|-------------------|--------------------|-------|---------|
| Center                  | Dundee            | 1 (0.2)            | 3 (0.9) | 4 (0.4) | <0.001 |
|                         | Imperial          | 134 (21.8)         | 43 (13.4) | 177 (18.9) |
|                         | Oxford            | 327 (53.3)         | 230 (71.7) | 557 (59.6) |
|                         | Technion          | 152 (24.8)         | 45 (14.0) | 197 (21.1) |
| EQ5D_Index              | Median (IQR)      | 0.7 (0.5 to 0.7)   | 0.8 (0.7 to 0.9) | 0.7 (0.6 to 0.8) | <0.001 |
| Depression_tscore       | Median (IQR)      | 52.0 (44.7 to 59.4) | 44.7 (38.2 to 50.9) | 49.4 (42.2 to 55.9) | <0.001 |
| Anxiety_tscore          | Median (IQR)      | 49.4 (40.7 to 58.4) | 40.7 (37.1 to 50.8) | 45.9 (37.1 to 56.4) | <0.001 |
| Sleep_Disturbance_tscore| Median (IQR)      | 56.3 (51.2 to 60.4) | 54.3 (48.1 to 59.4) | 56.3 (50.1 to 59.4) | 0.016 |
| Trauma                  | No                | 271 (44.1)         | 149 (46.4) | 420 (44.9) | 0.005 |
|                         | Yes               | 146 (23.8)         | 45 (14.0) | 191 (20.4) |
|                         | (Missing)         | 197 (32.1)         | 127 (39.6) | 324 (34.7) |
| Hospital_stay           | No                | 355 (57.8)         | 174 (54.2) | 529 (56.6) | 0.261 |
|                         | Yes               | 60 (9.8)           | 21 (6.5) | 81 (8.7) |
|                         | (Missing)         | 199 (32.4)         | 126 (39.3) | 325 (34.8) |
| TIPIExtraversion        | Median (IQR)      | 4.0 (2.5 to 5.0)   | 4.0 (3.0 to 5.0) | 4.0 (3.0 to 5.0) | 0.246 |
| TIPIAgreeableness       | Median (IQR)      | 5.0 (4.0 to 6.0)   | 5.0 (4.0 to 6.0) | 5.0 (4.0 to 6.0) | 0.345 |
| Variable                  | Median (IQR)            | | | | |
|---------------------------|-------------------------|---|---|---|---|
| TIPIConscientiousness     | 6.0 (4.5 to 6.5)        | 6.0 (5.0 to 7.0) | 6.0 (4.5 to 6.5) | 0.188 |
| TIPEmotionalStability     | 4.5 (3.5 to 6.5)        | 5.5 (4.0 to 6.5) | 5.0 (4.0 to 6.5) | 0.005 |
| TIPIOpenness              | 5.0 (4.0 to 6.0)        | 4.5 (4.0 to 5.5) | 5.0 (4.0 to 6.0) | 0.654 |
| Ever_smoked_status        | No                      | 203 (33.1)       | 108 (33.6)       | 311 (33.3) | 0.150 |
|                           | Yes                     | 211 (34.4)       | 86 (26.8)        | 297 (31.8) |
|                           | (Missing)               | 200 (32.6)       | 127 (39.6)       | 327 (35.0) |
| Alcohol_consumption       | Never                   | 151 (24.6)       | 48 (15.0)        | 199 (21.3) | 0.010 |
|                           | Less than 1 day per month | 82 (13.4)   | 37 (11.5)       | 119 (12.7) |
|                           | 1 to 3 days per month   | 52 (8.5)        | 23 (7.2)        | 75 (8.0) |
|                           | 1 or 2 days per week    | 68 (11.1)       | 34 (10.6)       | 102 (10.9) |
|                           | 3 or 4 days per week    | 25 (4.1)        | 19 (5.9)        | 44 (4.7) |
|                           | Daily or almost daily   | 37 (6.0)        | 32 (10.0)       | 69 (7.4) |
|                           | (Missing)               | 199 (32.4)      | 128 (39.9)      | 327 (35.0) |
| Alcohol_consumption_likert| Median (IQR)            | 1.0 (0.0 to 3.0) | 2.0 (1.0 to 4.0) | 1.0 (0.0 to 3.0) | <0.001 |
| Alcohol_status            | No                      | 151 (24.6)      | 48 (15.0)       | 199 (21.3) | 0.006 |
|                           | Yes                     | 264 (43.0)      | 145 (45.2)      | 409 (43.7) |
| Variable          | Median (IQR)       | Median (IQR)       | Median (IQR)       |
|-------------------|--------------------|--------------------|--------------------|
| PCS_score         | 15.0 (6.0 to 27.0) | 4.0 (0.0 to 11.0)  | 10.0 (3.0 to 23.0) |
| MNSI_score        | 6.0 (4.0 to 7.0)   | 3.0 (2.0 to 4.0)   | 5.0 (3.0 to 7.0)   |
| DN4_score         | 5.0 (4.0 to 7.0)   | 2.0 (1.0 to 3.0)   | 4.0 (3.0 to 6.0)   |
| Age               | 68.0 (59.0 to 73.0)| 70.0 (63.0 to 75.0)| 68.0 (60.0 to 74.0)|
| Gender            | Female 206 (33.6)  | 92 (28.7)          | 298 (31.9)         |
|                   | Male 408 (66.4)    | 228 (71.0)         | 636 (68.0)         |
|                   | (Missing) 0 (0.0)  | 1 (0.3)            | 1 (0.1)            |
| BMI               | 29.3 (26.0 to 33.3)| 28.4 (25.5 to 32.2)| 29.0 (26.0 to 33.0)|
| HBA1C             | 7.5 (6.7 to 8.7)   | 7.2 (6.5 to 8.2)   | 7.4 (6.6 to 8.5)   |
| Diabetes_Duration | 12.0 (6.0 to 17.0) | 15.5 (9.2 to 23.8) | 13.5 (8.0 to 20.0) |
| Cholesterol       | 4.0 (3.6 to 5.0)   | 4.2 (3.5 to 4.6)   | 4.1 (3.5 to 4.6)   |
| LDL               | 2.3 (1.8 to 3.1)   | 1.9 (1.7 to 2.5)   | 2.0 (1.7 to 2.8)   |
| HDL               | 1.1 (0.9 to 1.3)   | 1.2 (1.0 to 1.3)   | 1.2 (1.0 to 1.3)   |
| Creatinine        | 75.0 (65.0 to 85.0)| 80.0 (67.0 to 89.0)| 78.0               |
Table 3

Descriptive summary statistics for the validation dataset. Outcome variable indicates painful or painless DPN. Numerical variables are represented by the median and Inter Quantile Range (IQR) in brackets, categorical variables by the absolute occurrence and percentage in brackets. Columns hold from left to right data for people with Painful DPN, Painless DPN and the total of the Validation dataset. Right most column holds the p.value of the comparison between Painful and Painless DPN using the chi-square test for categorical variables or the Kruskal Walis test for numerical variables.

| TRIGLYCERIDES | Median (IQR) | Painful DPN | Painless DPN | Total | p.value |
|---------------|--------------|-------------|--------------|-------|---------|
|               | 1.7 (1.3 to 2.0) | 1.5 (1.2 to 2.0) | 1.7 (1.2 to 2.0) | 0.514 |

(IQR) (67.0 to 89.0)
| Dependent: Outcome          | Median (IQR) | Painful_neuropathy | Painless_neuropathy | Total | p.value |
|-----------------------------|--------------|--------------------|---------------------|-------|---------|
| EQ5D_Index                  | Median (IQR) | 0.6 (0.4 to 0.7)   | 0.7 (0.6 to 0.8)    | 0.7   | <0.001  |
| Depression_tscore           | Median (IQR) | 54.7 (41.1 to 60.5)| 48.9 (41.0 to 55.9) | 52.1  | <0.001  |
| Anxiety_tscore              | Median (IQR) | 51.7 (40.3 to 57.9)| 48.3 (40.3 to 54.1) | 51.4  | 0.001   |
| Sleep_Disturbance_tscore    | Median (IQR) | 51.5 (49.4 to 54.2)| 52.0 (49.7 to 54.5) | 51.8  | 0.128   |
| Trauma                      | No           | 107 (59.4)         | 73 (65.8)           | 180   | 0.289   |
|                             | Yes          | 66 (36.7)          | 33 (29.7)           | 99    | (34.0)  |
|                             | (Missing)    | 7 (3.9)            | 5 (4.5)             | 12    | (4.1)   |
| Hospital_stay               | No           | 144 (80.0)         | 82 (73.9)           | 226   | (77.7)  |
|                             | Yes          | 16 (8.9)           | 15 (13.5)           | 31    | (10.7)  |
|                             | (Missing)    | 20 (11.1)          | 14 (12.6)           | 34    | (11.7)  |
| TIPIExtraversion            | Median (IQR) | 4.0 (3.0 to 5.0)   | 4.0 (3.5 to 5.5)    | 4.0   | 0.077   |
| TIPIAgreeableness           | Median (IQR) | 5.0 (4.0 to 6.0)   | 5.0 (4.5 to 6.0)    | 5.0   | 0.161   |
| TIPIConscientiousness       | Median (IQR) | 5.5 (4.5 to 6.5)   | 5.5 (4.1 to 6.5)    | 5.5   | 0.600   |
| TIPIEmotionalStability      | Median (IQR) | 4.5 (4.0 to 5.5)   | 5.0 (4.0 to 6.5)    | 4.5   | 0.027   |
| TIPIOpenness                | Median (IQR) | 4.5 (3.5 to 5.5)   | 5.0 (4.0 to 6.0)    | 4.5   | 0.047   |
| Ever_smoked_status     |   |   |   |
|-----------------------|---|---|---|
| No                    | 71 (39.4) | 44 (39.6) | 115 (39.5) | 1.000 |
| Yes                   | 108 (60.0) | 66 (59.5) | 174 (59.8) |
| (Missing)             | 1 (0.6) | 1 (0.9) | 2 (0.7) |

| Alcohol_consumption     |   |   |   |
|------------------------|---|---|---|
| Never                  | 60 (33.3) | 27 (24.3) | 87 (29.9) | 0.358 |
| Less than 1 day per month | 45 (25.0) | 30 (27.0) | 75 (25.8) |
| 1 to 3 days per month  | 30 (16.7) | 19 (17.1) | 49 (16.8) |
| 1 or 2 days per week   | 16 (8.9) | 18 (16.2) | 34 (11.7) |
| 3 or 4 days per week   | 16 (8.9) | 8 (7.2) | 24 (8.2) |
| Daily or almost daily  | 11 (6.1) | 8 (7.2) | 19 (6.5) |
| (Missing)              | 2 (1.1) | 1 (0.9) | 3 (1.0) |

| Alcohol_consumption_likert | Median (IQR) | Median (IQR) | Median (IQR) | 0.134 |
|---------------------------|-------------|-------------|-------------|------|
| Median (IQR)              | 1.0 (0.0 to 2.0) | 1.0 (1.0 to 3.0) | 1.0 (0.0 to 3.0) |

| Alcohol_status     |   |   |   |
|---------------------|---|---|---|
| No                  | 60 (33.3) | 27 (24.3) | 87 (29.9) | 0.130 |
| Yes                 | 118 (65.6) | 83 (74.8) | 201 (69.1) |
| (Missing)           | 2 (1.1) | 1 (0.9) | 3 (1.0) |

| PCS_score     | Median (IQR) | Median (IQR) | Median (IQR) | <0.001 |
|---------------|-------------|-------------|-------------|------|
| Median (IQR)  | 11.0 (5.0 to 22.5) | 5.0 (1.0 to 15.0) | 8.5 (4.0 to 20.0) |

| MNSI_score     | Median (IQR) | Median (IQR) | Median (IQR) | <0.001 |
|----------------|-------------|-------------|-------------|------|
| Median (IQR)   | 5.0 (4.0 to 6.0) | 3.0 (3.0 to 4.0) | 4.0 (3.0 to 6.0) |
| Variable            | Median (IQR) | p-value |
|---------------------|-------------|---------|
| DN4_score           | 4.0 (3.0 to 5.0) | <0.001  |
|                      | 1.0 (0.0 to 1.0) |         |
|                      | 3.0 (2.0 to 5.0) |         |
| Age                 | 68.0 (63.0 to 77.0) | 0.590   |
|                      | 69.0 (63.5 to 76.0) |         |
|                      | 69.0 (63.0 to 77.0) |         |
| Gender              | Female       | 0.742   |
|                      | 66 (36.7)    |         |
|                      | 38 (34.2)    |         |
|                      | 104 (35.7)   |         |
| Male                | 113 (62.8)   |         |
|                      | 73 (65.8)    |         |
|                      | 186 (63.9)   |         |
| (Missing)           | 1 (0.6)      |         |
|                      | 0 (0.0)      |         |
|                      | 1 (0.3)      |         |
| BMI                 | 31.4 (28.3 to 36.4) | 0.204   |
|                      | 30.8 (27.2 to 34.4) |         |
|                      | 31.2 (27.8 to 35.3) |         |
| HBA1C               | 7.5 (6.8 to 8.9) | 0.311   |
|                      | 7.4 (6.7 to 8.4) |         |
|                      | 7.4 (6.7 to 8.7) |         |
| Diabetes_Duration   | 15.0 (12.0 to 19.5) | 0.921   |
|                      | 16.0 (12.0 to 21.5) |         |
|                      | 15.0 (12.0 to 20.0) |         |
| Cholesterol         | 3.9 (3.5 to 4.4) | 0.700   |
|                      | 3.9 (3.4 to 4.4) |         |
|                      | 3.9 (3.4 to 4.4) |         |
| LDL                 | 2.0 (1.5 to 2.5) | 0.591   |
|                      | 2.0 (1.6 to 2.5) |         |
|                      | 2.0 (1.5 to 2.5) |         |
| HDL                 | 1.1 (0.9 to 1.3) | 0.948   |
|                      | 1.1 (0.9 to 1.3) |         |
|                      | 1.1 (0.9 to 1.3) |         |
| Creatinine          | 79.5 (64.0 to 99.0) | 0.568   |
|                      | 82.0 (64.5 to 98.0) |         |
|                      | 80.0 (64.0 to 99.0) |         |
| TRIGLYCERIDES       | 1.8 (1.4 to 2.7) | 0.180   |
|                      | 1.7 (1.3 to 2.4) |         |
|                      | 1.8 (1.3 to 2.6) |         |
Figure 1

Flow diagram of the criteria used for outcome definition in the training and validation dataset.
Figure 2

Block diagram of the training and validation workflow. During model training statistical learning algorithms use cross-validation to fine tune their internal parameters in order to maximise MCC and estimate their predictive performance in new un-observed data. Multiple imputation by chained equation was used to impute missing values in the training datasets. A model has been trained in each imputed dataset and aggregated in the final model ensemble. During model validation the ensemble of trained models is used to predict un-observed instances. After outcome agnostic multiple imputation all trained models are being used to predict the outcome in all imputed validation sets. Then results are aggregated by majority voting.
Figure 3

Performance estimates during model training, aggregated across resamplings and imputations. Solid coloured bars show the estimate mean and black lines the pooled SD calculated using Rubin’s rules. Visualised scalar metrics are the Mathews Correlation Coefficient (MCC), Balanced Accuracy and Area Under the Precision Recall Curve (AUPRC).
Pooled Variable Importance

Figure 4

Pooled model specific variable importance across resamplings and imputations. Variable importance has been scaled from 0 to 100 to be directly comparable, coloured bars represent the mean, solid black lines the pooled SD calculated using Rubin’s rules, dots represent the variable importance estimated for each imputation. A,C: Mean reduction of classification accuracy when removing each independent variable in Adaptive Regression Splines. B, E: Gini coefficient that quantifies mean decrease of node impurity of the nodes produced by a split that uses each variable in a Random Forest. C: ROC analysis for each independent variable in Naive Bayes classifier.
Partial dependence plots Painful Neuropathy, Adaptive Regression Splines

Figure 5

Partial Dependence (PD) plots for the Adaptive Regression Splines model aggregated across imputations. For panels A – D: Y-axis show the average marginal effect on the prediction given a certain value of the respective variable/feature. X-axis show the feature's values and the rug of marks under the x-axis indicate the density of data distribution across the feature's full range. Black lines with yellow outline represent the aggregated PD. Blue lines show the fitted smoothed LOESS curve and highlight the PD trend. Selected independent variables had a scaled importance of > 10 and are arranged by decreasing importance value.
Partial Dependence (PD) plots for the Random Forest model aggregated across imputations. For panels A – L: Y-axis show the average marginal effect on the prediction given a certain value of the respective variable/feature. X-axis show the feature's values and the rug of marks under the x-axis indicate the density of data distribution across the feature's full range. Black lines with yellow outline represent the aggregated PD. Blue lines show the fitted smoothed LOESS curve and highlight the PD trend. Selected independent variables had a scaled importance of > 10 and are arranged by decreasing importance value.
Partial dependence plots for Painful Neuropathy, Naive Bayes

Figure 7

Partial Dependence (PD) plots for the Naive Bayes classifier aggregated across imputations. For panels A – I: Y-axis show the average marginal effect on the prediction given a certain value of the respective variable/feature. X-axis show the feature's values and the rug of marks under the x-axis indicate the density of data distribution across the feature's full range. Black lines with yellow outline represent the aggregated PD. Blue lines show the fitted smoothed LOESS curve and highlight the PD trend. Selected independent variables had a scaled importance of > 10 and are arranged by decreasing importance value.
Figure 8

Model performance in the independent validation dataset. A: Scalar performance metrics. From left to right: Accuracy, the p.value of the negative binomial test with the null hypothesis that accuracy is not higher than the prevalence of the majority class, Balanced Accuracy, Mathews Correlation Coefficient, Area Under the Precision Recall Curve. A - C: Average performance estimates during training – red dots, versus performance achieved on the independent validation dataset – blue dots.
**Model calibration on validation dataset**

**A**

![Graph A](image)

- Y-axis shows the observed event rate on the validation set.
- X-axis shows the predicted probability binned into 10 deciles.
- Colour coded lines show the event rate vs the midpoint of the probability decile for each model.

**B**

![Graph B](image)

- The slope and intercept of a linear model fitted to the data of panel A, event rate = A*probability decile + b.

### Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supplementaldata.pdf